{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:46Z","timestamp":1740144166357,"version":"3.37.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40273-024-01414-7","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T16:02:44Z","timestamp":1722960164000},"page":"1255-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-4758","authenticated-orcid":false,"given":"Johanna","family":"Lister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1739-6852","authenticated-orcid":false,"given":"Suzy","family":"Paisley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-8503","authenticated-orcid":false,"given":"Christopher","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":false,"given":"Paul","family":"Tappenden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"12","key":"1414_CR1","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.3390\/ijerph6122950","volume":"6","author":"S Simoens","year":"2009","unstructured":"Simoens S. Health economic assessment: a methodological primer. Int J Environ Res Public Health. 2009;6(12):2950\u201366.","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"1414_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/13696998.2017.1359182","volume":"20","author":"T Philipson","year":"2017","unstructured":"Philipson T, MacEwan JP. The importance of model inputs and assumptions in conducting health technology assessments of novel drugs. J Med Econ. 2017;20(10):1107\u20139.","journal-title":"J Med Econ"},{"issue":"3","key":"1414_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0266462305050403","volume":"21","author":"S Golder","year":"2005","unstructured":"Golder S, Glanville J, Ginnelly L. Populating decision-analytic models: the feasibility and efficiency of database searching for individual parameters. Int J Technol Assess Health Care. 2005;21(3):305\u201311.","journal-title":"Int J Technol Assess Health Care"},{"key":"1414_CR4","doi-asserted-by":"crossref","unstructured":"Philips Z, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8(36):iii\u2013xi, 1.","DOI":"10.3310\/hta8360"},{"issue":"6","key":"1414_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40273-015-0372-x","volume":"34","author":"S Paisley","year":"2016","unstructured":"Paisley S. Identification of evidence for key parameters in decision-analytic models of cost effectiveness: a description of sources and a recommended minimum search requirement. Pharmacoeconomics. 2016;34(6):597\u2013608.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1414_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","volume":"22","author":"J Brazier","year":"2019","unstructured":"Brazier J, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267\u201375.","journal-title":"Value Health"},{"issue":"1","key":"1414_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/jrsm.1282","volume":"9","author":"A Delaney","year":"2018","unstructured":"Delaney A, Tam\u00e1s PA. Searching for evidence or approval? A commentary on database search in systematic reviews and alternative information retrieval methodologies. Res Synth Methods. 2018;9(1):124\u201331.","journal-title":"Res Synth Methods"},{"issue":"6","key":"1414_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1440-172X.2001.00295.x","volume":"7","author":"JM Magarey","year":"2001","unstructured":"Magarey JM. Elements of a systematic review. Int J Nurs Pract. 2001;7(6):376\u201382.","journal-title":"Int J Nurs Pract"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1108\/eb024320","volume":"13","author":"MJ Bates","year":"1989","unstructured":"Bates MJ. The design of browsing and berrypicking techniques for the online search interface. Online Rev. 1989;13:407\u201324.","journal-title":"Online Rev"},{"key":"1414_CR10","doi-asserted-by":"crossref","unstructured":"Preston L, et al. Improving search efficiency for systematic reviews of diagnostic test accuracy: an exploratory study to assess the viability of limiting to MEDLINE, EMBASE and reference checking. Improving search efficiency for systematic reviews of diagnostic test accuracy: an exploratory study to assess the viability of limiting to MEDLINE, EMBASE and reference checking. Syst Rev. 2015;4(82).","DOI":"10.1186\/s13643-015-0074-7"},{"issue":"3","key":"1414_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/0163278710388029","volume":"34","author":"M Pearson","year":"2011","unstructured":"Pearson M, Moxham T, Ashton K. Effectiveness of search strategies for qualitative research about barriers and facilitators of program delivery. Eval Health Prof. 2011;34(3):297\u2013308.","journal-title":"Eval Health Prof"},{"issue":"7172","key":"1414_CR12","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1136\/bmj.317.7172.1562","volume":"317","author":"RJ McManus","year":"1998","unstructured":"McManus RJ, et al. Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews. BMJ. 1998;317(7172):1562\u20133.","journal-title":"BMJ"},{"issue":"1","key":"1414_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13643-016-0337-y","volume":"5","author":"J Adams","year":"2016","unstructured":"Adams J, et al. Searching and synthesising \u2018grey literature\u2019 and \u2018grey information\u2019 in public health: critical reflections on three case studies. Syst Rev. 2016;5(1):164.","journal-title":"Syst Rev"},{"issue":"1","key":"1414_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13643-016-0249-x","volume":"5","author":"A Booth","year":"2016","unstructured":"Booth A. Searching for qualitative research for inclusion in systematic reviews: a structured methodological review. Syst Rev. 2016;5(1):74.","journal-title":"Syst Rev"},{"key":"1414_CR15","unstructured":"Kaltenthaler E, Tappenden P, Paisley S. NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models. 2011: Sheffield."},{"key":"1414_CR16","doi-asserted-by":"crossref","unstructured":"Paynter RA, Featherstone R, Stoeger E, et al. A prospective comparison of evidence synthesis search strategies developed with and without text-mining tools. J Clin Epidemiol. 2021.","DOI":"10.23970\/AHRQEPCMETHODSPROSPECTIVECOMPARISON"},{"key":"1414_CR17","unstructured":"Archer RJ, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy: protocol record CRD42013006883. 2013."},{"issue":"3","key":"1414_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hir.12276","volume":"36","author":"A Sutton","year":"2019","unstructured":"Sutton A, et al. Meeting the review family: exploring review types and associated information retrieval requirements. Health Inf Libr J. 2019;36(3):202\u201322.","journal-title":"Health Inf Libr J"},{"issue":"2","key":"1414_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1473325007077257","volume":"6","author":"G Mackay","year":"2007","unstructured":"Mackay G. Is there a need to differentiate between qualitative and quantitative searching strategies for literature reviewing? Qual Soc Work. 2007;6(2):231\u201341.","journal-title":"Qual Soc Work"},{"issue":"7","key":"1414_CR20","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1111\/j.1365-2648.2011.05636.x","volume":"67","author":"K Hannes","year":"2011","unstructured":"Hannes K, Lockwood C. Pragmatism as the philosophical foundation for the Joanna Briggs meta-aggregative approach to qualitative evidence synthesis. J Adv Nurs. 2011;67(7):1632\u201342.","journal-title":"J Adv Nurs"},{"issue":"1","key":"1414_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13643-017-0425-7","volume":"6","author":"L Hartling","year":"2017","unstructured":"Hartling L, et al. Fit for purpose: perspectives on rapid reviews from end-user interviews. Syst Rev. 2017;6(1):32\u201332.","journal-title":"Syst Rev"},{"issue":"11","key":"1414_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.1445-2197.2008.04730.x","volume":"78","author":"A Watt","year":"2008","unstructured":"Watt A, et al. Rapid versus full systematic reviews: validity in clinical practice? ANZ J Surg. 2008;78(11):1037\u201340.","journal-title":"ANZ J Surg"},{"key":"1414_CR23","unstructured":"NICE. NICE health technology evaluations: the manual. Process and methods. 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741."},{"issue":"8","key":"1414_CR24","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s11136-015-0926-6","volume":"24","author":"J Richardson","year":"2015","unstructured":"Richardson J, Iezzi A, Khan MA. Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and \u201cmicro-utility\u201d effects. Qual Life Res. 2015;24(8):2045\u201353.","journal-title":"Qual Life Res"},{"issue":"9","key":"1414_CR25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier J, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873\u201384.","journal-title":"Health Econ"},{"issue":"1","key":"1414_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/ecco-jcc\/jju005","volume":"9","author":"L Alrubaiy","year":"2015","unstructured":"Alrubaiy L, et al. Development of a short questionnaire to assess the quality of life in Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2015;9(1):66\u201376.","journal-title":"J Crohns Colitis"},{"key":"1414_CR27","first-page":"15","volume":"15","author":"L Biedermann","year":"2022","unstructured":"Biedermann L, et al. Health-related quality of life outcomes with tofacitinib treatment in patients with ulcerative colitis in the open-label extension study, OCTAVE open. Inflamm Bowel Dis. 2022;15:15.","journal-title":"Inflamm Bowel Dis"},{"issue":"Supplement_1","key":"1414_CR28","doi-asserted-by":"publisher","first-page":"i324","DOI":"10.1093\/ecco-jcc\/jjab232.420","volume":"16","author":"J Burisch","year":"2022","unstructured":"Burisch J, et al. P293 Insights from patients with ulcerative colitis on disease burden: findings from a real-world survey in Europe. J Crohn\u2019s Colitis. 2022;16(Supplement_1):i324\u20135.","journal-title":"J Crohn's Colitis"},{"key":"1414_CR29","unstructured":"Casellas F, L\u00f3pez Vivancos J, Malagela JR. Previous experience and quality of life in patients with inflammatory bowel disease during relapse. Rev Esp Enferm Dig. 2003;95(7):476\u20139, 471\u20135."},{"issue":"11","key":"1414_CR30","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1007\/s10620-020-06707-3","volume":"66","author":"PS Dulai","year":"2021","unstructured":"Dulai PS, Jairath V. A microsimulation model to project the 5-year impact of using hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for acute flares. Dig Dis Sci. 2021;66(11):3740\u201352.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"1414_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/13696998.2018.1484371","volume":"21","author":"A Gherardi","year":"2018","unstructured":"Gherardi A, et al. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ. 2018;21(9):869\u201377.","journal-title":"J Med Econ"},{"issue":"5","key":"1414_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/03007995.2020.1716704","volume":"36","author":"LM Hagelund","year":"2020","unstructured":"Hagelund LM, Elkjaer Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis\u2014results from a survey study. Curr Med Res Opin. 2020;36(5):771\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1414_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40273-019-00841-1","volume":"38","author":"L Hernandez","year":"2020","unstructured":"Hernandez L, et al. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-tnf-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2020;38(1):69\u201384.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1414_CR34","first-page":"573","volume":"32","author":"G Richardson","year":"2001","unstructured":"Richardson G, et al. Quality of life in inflammatory bowel disease: a cross-cultural comparison of English and Canadian children. J Pediatr Gastroenterol Nutr. 2001;32(5):573\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"1414_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ecco-jcc\/jjz212","volume":"14","author":"FI Scott","year":"2020","unstructured":"Scott FI, et al. Identification of the most cost-effective position of vedolizumab among the available biologic drugs for the treatment of ulcerative colitis. J Crohns Colitis. 2020;14(5):575\u201387.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"1414_CR36","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/ecco-jcc\/jjv134","volume":"9","author":"ME van der Valk","year":"2015","unstructured":"van der Valk ME, et al. Comparison of costs and quality of life in ulcerative colitis patients with an ileal pouch-anal anastomosis, ileostomy and anti-TNFalpha therapy. J Crohns Colitis. 2015;9(11):1016\u201323.","journal-title":"J Crohns Colitis"},{"key":"1414_CR37","unstructured":"Canadian Agency for Drugs and Technologies in Health, Pharmacoeconomic Review Report: Tofacitinib (Xeljanz): (Pfizer Canada Inc.): Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response, or intolerance to either conventional UC therapy or a tumour necrosis factor alpha inhibitor [Internet]. Mar 2019: Ottawa, Ontario. Canada."},{"key":"1414_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13554-012-0007-0","volume":"3","author":"MA Chaudhary","year":"2013","unstructured":"Chaudhary MA, Fan T. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands. Biol Ther. 2013;3:45\u201360.","journal-title":"Biol Ther"},{"issue":"4","key":"1414_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/ajg.2011.39","volume":"106","author":"AK Waljee","year":"2011","unstructured":"Waljee AK, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106(4):794\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1414_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.crohns.2009.11.010","volume":"4","author":"CD Poole","year":"2010","unstructured":"Poole CD, et al. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010;4(3):275\u201382.","journal-title":"J Crohns Colitis"},{"key":"1414_CR41","unstructured":"NICE, Vedolizumab for treating moderately to severely active ulcerative colitis [TA342] committee papers. 2015."},{"issue":"1","key":"1414_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","volume":"20","author":"A Armuzzi","year":"2020","unstructured":"Armuzzi A, et al. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC Gastroenterol. 2020;20(1):18.","journal-title":"BMC Gastroenterol"},{"key":"1414_CR43","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/j.1365-2036.2008.03839.x","volume":"28","author":"HH Tsai","year":"2008","unstructured":"Tsai HH, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28:1230\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"1414_CR44","first-page":"A153","volume":"57","author":"A Woehl","year":"2008","unstructured":"Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis. Gut. 2008;57(Suppl. 1):A153.","journal-title":"Gut"},{"key":"1414_CR45","unstructured":"Vaizey C, et al. Disease status, patient quality of life, and health care resource use for ulcerative colitis in the United Kingdom: an observational study. Frontline Gastroenterol. 2014;0:1\u20137."},{"key":"1414_CR46","unstructured":"Swinburn P, et al. The impact of surgery on health related quality of life in ulcerative colitis. In: Gut conference: digestive disorders federation meeting. Liverpool."},{"key":"1414_CR47","unstructured":"NICE, Ozanimod for treating moderate to severe ulcerative colitis committee papers TA828. 2022."},{"issue":"1","key":"1414_CR48","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/13696998.2021.1881323","volume":"24","author":"A Sardesai","year":"2021","unstructured":"Sardesai A, et al. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ. 2021;24(1):279\u201390.","journal-title":"J Med Econ"},{"key":"1414_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jval.2011.08.004","volume":"15","author":"R Leidl","year":"2012","unstructured":"Leidl R, et al. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease. Value Health. 2012;15:151\u20137.","journal-title":"Value Health"},{"issue":"4","key":"1414_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1017\/S0266462310000966","volume":"26","author":"A Booth","year":"2010","unstructured":"Booth A. How much searching is enough? Comprehensive versus optimal retrieval for technology assessments. Int J Technol Assess Health Care. 2010;26(4):431\u20135.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"1414_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/hir.12009","volume":"30","author":"FR Beyer","year":"2013","unstructured":"Beyer FR, Wright K. Can we prioritise which databases to search? A case study using a systematic review of frozen shoulder management. Health Inf Libr J. 2013;30(1):49\u201358.","journal-title":"Health Inf Libr J"},{"issue":"1","key":"1414_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13643-015-0074-7","volume":"4","author":"L Preston","year":"2015","unstructured":"Preston L, et al. Improving search efficiency for systematic reviews of diagnostic test accuracy: an exploratory study to assess the viability of limiting to MEDLINE, EMBASE and reference checking. Syst Rev. 2015;4(1):82.","journal-title":"Syst Rev"},{"issue":"11","key":"1414_CR53","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/1055-9965.EPI-17-0230","volume":"26","author":"G Ertaylan","year":"2017","unstructured":"Ertaylan G, et al. A comparative study on the WCRF international\/university of Bristol methodology for systematic reviews of mechanisms underpinning exposure-cancer associations. Cancer Epidemiol Biomark Prev. 2017;26(11):1583\u201394.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"1414_CR54","first-page":"253","volume":"110","author":"ML Rethlefsen","year":"2022","unstructured":"Rethlefsen ML, Page MJ. PRISMA 2020 and PRISMA-S: common questions on tracking records and the flow diagram. J Med Libr Assoc. 2022;110(2):253\u20137.","journal-title":"J Med Libr Assoc"},{"key":"1414_CR55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","volume":"4","author":"KO Arseneau","year":"2006","unstructured":"Arseneau KO, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1414_CR56","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.dld.2016.01.011","volume":"48","author":"G Van Assche","year":"2016","unstructured":"Van Assche G, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months\u2014multicenter European cohort study. Dig Liver Dis. 2016;48(6):592\u2013600.","journal-title":"Dig Liver Dis"},{"key":"1414_CR57","doi-asserted-by":"publisher","first-page":"5315798","DOI":"10.1155\/2016\/5315798","volume":"2016","author":"CL Beilman","year":"2016","unstructured":"Beilman CL, et al. Real-life treatment paradigms show adalimumab is cost-effective for the management of ulcerative colitis. Can J Gastroenterol Hepatol. 2016;2016:5315798.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1414_CR58","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.crohns.2013.11.017","volume":"8","author":"PR Gibson","year":"2014","unstructured":"Gibson PR, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohn\u2019s Colitis. 2014;8:598\u2013606.","journal-title":"J Crohn's Colitis"},{"issue":"1","key":"1414_CR59","first-page":"61","volume":"13","author":"P Kawalec","year":"2018","unstructured":"Kawalec P, Stawowczyk E. Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. Przeglad gastroenterologiczny. 2018;13(1):61\u20138.","journal-title":"Przeglad gastroenterologiczny"},{"key":"1414_CR60","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/DCR.0b013e3182690870","volume":"55","author":"K Kuruvilla","year":"2012","unstructured":"Kuruvilla K, Osler T, Hyman NH. A comparison of the quality of life of ulcerative colitis patients after IPAA vs ileostomy. Dis Colon Rectum. 2012;55:1131\u20137.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"1414_CR61","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/0016-5085(91)90081-U","volume":"101","author":"RS McLeod","year":"1991","unstructured":"McLeod RS, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101(5):1307\u201313.","journal-title":"Gastroenterology"},{"key":"1414_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10198-009-0199-5","volume":"11","author":"YS Punekar","year":"2010","unstructured":"Punekar YS, Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ. 2010;11:67\u201376.","journal-title":"Eur J Health Econ"},{"key":"1414_CR63","unstructured":"NICE, Filgotinib for treating moderately to severely active ulcerative colitis TA792 [ID3736] Committee Papers. 2022."},{"issue":"1","key":"1414_CR64","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12913-023-09233-w","volume":"23","author":"MF Alam","year":"2023","unstructured":"Alam MF, et al. Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial. BMC Health Serv Res. 2023;23(1):226.","journal-title":"BMC Health Serv Res"},{"key":"1414_CR65","unstructured":"MDS, Manufacturer Submission of Evidence: Infliximab (Remicade). Submission to NICE 2014."},{"key":"1414_CR66","unstructured":"MDS, Manufacturer Submission of Evidence: Golimumab (Simponi). Submission to NICE, 2014."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01414-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01414-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:05:40Z","timestamp":1729703140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01414-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01414-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"4 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JL, SP and CC have no relevant financial or non-financial interests to disclose.\u00a0PT\u00a0is an Editorial Board Member of PharmacoEconomics. He\u00a0was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. PT has no relevant financial interests to disclose.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.L., S.P., P.T. and C.C. contributed to the study\u2019s conception and design, including selection of alternative search methods. J.L. reviewed the literature, wrote the first draft and made the edits to the manuscript. S.P., P.T. and C.C. reviewed and critiqued versions of the manuscript for important intellectual content. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}